Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction Chemoimmunotherapy + RT for Esophageal Cancer
NCT07015489Phase 2Completed
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jan 2022
- Primary completion
- May 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Jiangsu Provincial People's Hospital. Started Jan 2022; status: completed.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07015489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07015489.